<DOC>
	<DOCNO>NCT01086020</DOCNO>
	<brief_summary>Atherosclerosis progressive disease . Lipid lower therapy standard treatment patient coronary artery disease . Studies indicate coronary artery plaque progression positive relationship plasma cholesterol level , could halt reversed intensive statin therapy ( 20-40 mg/d atorvastatin ) . Ezetimibe plus statin could lower blood cholesterol level . Here investigator hypothesize cholesterol lower level rout dose atorvastatin low dose atorvastatin plus ezetimibe could achieve effect coronary artery plaque cessation regression .</brief_summary>
	<brief_title>Atorvastatin Plus Ezetimibe Coronary Plaque Progression</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Willing receive coronary angiography potential PCI therapy Patients treat statin randomization Patient ≤ 20 % ≥ 70 % coronary narrowing target lesion ST elevation myocardial infarction le 7 day Without informed consent Abnormal liver function randomization , ( AST , ALT ≥ULN ) Active hepatitis muscular disease Impaired renal function serum creatinine level &gt; 3mg/dl Impaired leave ventricular function LVEF &gt; 30 % Participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>IVUS</keyword>
	<keyword>coronary plaque</keyword>
	<keyword>regression</keyword>
</DOC>